Drug recall · February 2, 2022
Pioglitazone Tablets USP recall
Why: Superpotent and Failed Tablet/Capsule Specifications
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Pioglitazone Tablets USP, 45 mg, 500 count bottles, Distributed by: Aurobindo Pharma USA, Inc., East Windsor, NJ -- NDC 57237-221-05
- Lots / codes
Batch # PF4520028B & PF4520028A, Exp. Date 11/2022
- Quantity
- 792 bottles
- Company
- Aurobindo Pharma USA Inc., East Windsor, NJ
- Distribution
- Nationwide in the US
- Initiated
- December 29, 2021 · Voluntary: Firm initiated
- Classified
- January 24, 2022
- Reported
- February 2, 2022
- Ended
- December 4, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Pioglitazone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.